메뉴 건너뛰기




Volumn 26, Issue 1, 2014, Pages 1-6

Emerging therapies in antineutrophil cytoplasm antibody-associated vasculitis

Author keywords

antineutrophil cytoplasm antibody associated vasculitis; biologics; rituximab; treatment

Indexed keywords

15 DEOXYSPERGUALIN; ABATACEPT; ADALIMUMAB; ALEMTUZUMAB; AZATHIOPRINE; BELIMUMAB; BORTEZOMIB; COMPLEMENT; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A; CYCLOPHOSPHAMIDE; CYTOKINE; ETANERCEPT; FINGOLIMOD; FOSTAMATINIB; GLUCOCORTICOID; INFLIXIMAB; MEPOLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PIRFENIDONE; PLACEBO; RITUXIMAB; TOCILIZUMAB; TOFACITINIB; USTEKINUMAB;

EID: 84890188767     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000005     Document Type: Review
Times cited : (16)

References (50)
  • 1
    • 0020656868 scopus 로고
    • Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years
    • Fauci AS, Haynes BF, Katz P, et al. Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98:76-85.
    • (1983) Ann Intern Med , vol.98 , pp. 76-85
    • Fauci, A.S.1    Haynes, B.F.2    Katz, P.3
  • 2
    • 66149168812 scopus 로고    scopus 로고
    • Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibodyassociated vasculitis: A randomized controlled trial
    • De Groot K, Harper L, Jayne DRW, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibodyassociated vasculitis: A randomized controlled trial. Ann Intern Med 2009; 150:670-680.
    • (2009) Ann Intern Med , vol.150 , pp. 670-680
    • De Groot, K.1    Harper, L.2    Jayne, D.R.W.3
  • 3
    • 0038122889 scopus 로고    scopus 로고
    • A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies
    • Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44.
    • (2003) N Engl J Med , vol.349 , pp. 36-44
    • Jayne, D.1    Rasmussen, N.2    Andrassy, K.3
  • 4
    • 84856383829 scopus 로고    scopus 로고
    • Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis
    • Walsh M, Flossmann O, Berden A, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64:542-548.
    • (2012) Arthritis Rheum , vol.64 , pp. 542-548
    • Walsh, M.1    Flossmann, O.2    Berden, A.3
  • 5
    • 77955236779 scopus 로고    scopus 로고
    • Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis
    • Walsh M, Merkel PA, Mahr A, et al. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res 2010; 62:1166-1173.
    • (2010) Arthritis Care Res , vol.62 , pp. 1166-1173
    • Walsh, M.1    Merkel, P.A.2    Mahr, A.3
  • 6
    • 78649728808 scopus 로고    scopus 로고
    • Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial
    • Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled trial. JAMA 2010; 304:2381-2388.
    • (2010) JAMA , vol.304 , pp. 2381-2388
    • Hiemstra, T.F.1    Walsh, M.2    Mahr, A.3
  • 7
    • 77749277070 scopus 로고    scopus 로고
    • Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement - A prospective, open-label pilot trial
    • Silva F, Specks U, Kalra S, et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement - A prospective, open-label pilot trial. Clin J Am Soc Nephrol 2010; 5:445-453.
    • (2010) Clin J Am Soc Nephrol , Issue.5 , pp. 445-453
    • Silva, F.1    Specks, U.2    Kalra, S.3
  • 8
    • 42949083859 scopus 로고    scopus 로고
    • Mycophenolatemofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement
    • Hu W, Liu C, Xie H, et al. Mycophenolatemofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008; 23:1307-1312.
    • (2008) Nephrol Dial Transplant , vol.23 , pp. 1307-1312
    • Hu, W.1    Liu, C.2    Xie, H.3
  • 9
    • 0037305174 scopus 로고    scopus 로고
    • 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: A six-month open-label trial to evaluate safety and efficacy
    • Birck R, Warnatz K, Lorenz HM, et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: A six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003; 14:440-447.
    • (2003) J Am Soc Nephrol , vol.14 , pp. 440-447
    • Birck, R.1    Warnatz, K.2    Lorenz, H.M.3
  • 10
    • 79952928275 scopus 로고    scopus 로고
    • Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: A meta-analysis
    • Walsh M, Catapano F, Szpirt W, et al. Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: A meta-analysis. Am J Kidney Dis 2011; 57:566-574.
    • (2011) Am J Kidney Dis , vol.57 , pp. 566-574
    • Walsh, M.1    Catapano, F.2    Szpirt, W.3
  • 11
    • 84874932394 scopus 로고    scopus 로고
    • Plasma exchange and glucocorticoid dosing in the treatment of antineutrophil cytoplasm antibody associated vasculitis (PEXIVAS): Protocol for a randomized controlled trial
    • Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoid dosing in the treatment of antineutrophil cytoplasm antibody associated vasculitis (PEXIVAS): Protocol for a randomized controlled trial. Trials 2013; 14:73.
    • (2013) Trials , Issue.14 , pp. 73
    • Walsh, M.1    Merkel, P.A.2    Peh, C.A.3
  • 12
    • 25444502877 scopus 로고    scopus 로고
    • Is PR3-ANCA formation initiated in wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production
    • Voswinkel J, Müller A, Lamprecht P. Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann N Y Acad Sci 2005; 1051:12-19.
    • (2005) Ann N Y Acad Sci , vol.1051 , pp. 12-19
    • Voswinkel, J.1    Müller, A.2    Lamprecht, P.3
  • 13
    • 33745697938 scopus 로고    scopus 로고
    • B lymphocyte maturation in Wegener's granulomatosis: A comparative analysis of VH genes from endonasal lesions
    • Voswinkel J, Müller A, Kraemer JA, et al. B lymphocyte maturation in Wegener's granulomatosis: A comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006; 65:859-864.
    • (2006) Ann Rheum Dis , vol.65 , pp. 859-864
    • Voswinkel, J.1    Müller, A.2    Kraemer, J.A.3
  • 14
    • 27844456394 scopus 로고    scopus 로고
    • BAFF is elevated in the serum of patients with Wegener's granulomatosis
    • Krumbholz M, Specks U, Wick M, et al. BAFF is elevated in the serum of patients with Wegener's granulomatosis. J Autoimmun 2005; 25:298-302.
    • (2005) J Autoimmun , vol.25 , pp. 298-302
    • Krumbholz, M.1    Specks, U.2    Wick, M.3
  • 15
    • 0020051506 scopus 로고
    • Suppression of human B lymphocyte function by cyclophosphamide
    • Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982; 128:2453-2457.
    • (1982) J Immunol , vol.128 , pp. 2453-2457
    • Cupps, T.R.1    Edgar, L.C.2    Fauci, A.S.3
  • 16
    • 0036790387 scopus 로고    scopus 로고
    • Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice
    • Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110:955-963.
    • (2002) J Clin Invest , vol.110 , pp. 955-963
    • Xiao, H.1    Heeringa, P.2    Hu, P.3
  • 17
    • 84855674846 scopus 로고    scopus 로고
    • Antiproteinase 3 antineutrophilcytoplasmautoantibodiesrecapitulatesystemic vasculitis in mice with a humanized immune system
    • Little MA, Al-Ani B, Ren S, et al. Antiproteinase 3 antineutrophilcytoplasmautoantibodiesrecapitulatesystemic vasculitis in mice with a humanized immune system. PLoS One 2012; 7:e28626.
    • (2012) PLoS One , Issue.7
    • Little, M.A.1    Al-Ani, B.2    Ren, S.3
  • 18
    • 77954651554 scopus 로고    scopus 로고
    • Rituximab versus cyclophosphamide for ANCA-associated vasculitis
    • Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221-232.
    • (2010) N Engl J Med , Issue.363 , pp. 221-232
    • Stone, J.H.1    Merkel, P.A.2    Spiera, R.3
  • 19
    • 77954632414 scopus 로고    scopus 로고
    • Rituximab versus cyclophosphamide in ANCA-associatedrenalvasculitis
    • Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associatedrenalvasculitis. N Engl J Med 2010; 363:211-220.
    • (2010) N Engl J Med , Issue.363 , pp. 211-220
    • Jones, R.B.1    Tervaert, J.W.2    Hauser, T.3
  • 20
    • 84880882979 scopus 로고    scopus 로고
    • Efficacy of remission-induction regimens for ANCA-associated vasculitis
    • Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369:417-427.
    • (2013) N Engl J Med , Issue.369 , pp. 417-427
    • Specks, U.1    Merkel, P.A.2    Seo, P.3
  • 21
    • 84868087895 scopus 로고    scopus 로고
    • Rituximab for remission maintenance in relapsing ANCA-associated vasculitis
    • Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis Rheum 2012; 64:3760- 3769.
    • (2012) Arthritis Rheum , Issue.64 , pp. 3760-3769
    • Smith, R.M.1    Jones, R.B.2    Guerry, M.J.3
  • 22
    • 77955767712 scopus 로고    scopus 로고
    • Rituximab as maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis
    • Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010; 5:1394-1400.
    • (2010) Clin J Am Soc Nephrol , Issue.5 , pp. 1394-1400
    • Rhee, E.P.1    Laliberte, K.A.2    Niles, J.L.3
  • 23
    • 84868012506 scopus 로고    scopus 로고
    • Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten-year experience at a single center
    • Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): Ten-year experience at a single center. Arthritis Rheum 2012; 64:3770- 3778.
    • (2012) Arthritis Rheum , Issue.64 , pp. 3770-3778
    • Cartin-Ceba, R.1    Golbin, J.M.2    Keogh, K.A.3
  • 24
    • 84889645482 scopus 로고    scopus 로고
    • Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: Results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
    • Epub ahead of print]
    • Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: Results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2013. [Epub ahead of print]
    • (2013) Ann Rheum Dis
    • Wallace, D.J.1    Kalunian, K.2    Petri, M.A.3
  • 25
    • 84879502096 scopus 로고    scopus 로고
    • Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: Results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up
    • Wallace DJ, Gordon C, Strand V, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: Results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford) 2013; 52:1313-1322.
    • (2013) Rheumatology (Oxford) , Issue.52 , pp. 1313-1322
    • Wallace, D.J.1    Gordon, C.2    Strand, V.3
  • 27
    • 84863116877 scopus 로고    scopus 로고
    • Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy
    • Berden AE, Jones RB, Erasmus DD, et al. Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. J Am SocNephrol 2012; 23:313-321.
    • (2012) J Am SocNephrol , Issue.23 , pp. 313-321
    • Berden, A.E.1    Jones, R.B.2    Erasmus, D.D.3
  • 28
    • 50249107909 scopus 로고    scopus 로고
    • Long-term follow-up of relapsing/refractoryanti- neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H
    • Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/ refractoryanti- neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 2008; 67:1322-1327.
    • (2008) Ann Rheum Dis , vol.67 , pp. 1322-1327
    • Walsh, M.1    Chaudhry, A.2    Jayne, D.3
  • 29
    • 67349223570 scopus 로고    scopus 로고
    • Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauciimmune vasculitis
    • Xing GQ, Chen M, Liu G, et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauciimmune vasculitis. J Clin Immunol 2009; 29:282-291.
    • (2009) J Clin Immunol , vol.29 , pp. 282-291
    • Xing, G.Q.1    Chen, M.2    Liu, G.3
  • 30
    • 33847052568 scopus 로고    scopus 로고
    • Alternative complement pathway in the pathogenesis of disease mediated by antineutrophil cytoplasmic autoantibodies
    • Xiao H, Schreiber A, Heeringa P, et al. Alternative complement pathway in the pathogenesis of disease mediated by antineutrophil cytoplasmic autoantibodies. Am J Pathol 2007; 170:52-64.
    • (2007) Am J Pathol , vol.170 , pp. 52-64
    • Xiao, H.1    Schreiber, A.2    Heeringa, P.3
  • 31
    • 84861981026 scopus 로고    scopus 로고
    • C5a and its receptors in human antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
    • Yuan J, Gou SJ, Huang J, et al. C5a and its receptors in human antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res Ther 2012; 14:R140.
    • (2012) Arthritis Res Ther , Issue.14
    • Yuan, J.1    Gou, S.J.2    Huang, J.3
  • 32
    • 2642680076 scopus 로고    scopus 로고
    • Active Wegener's granulomatosis is associated with HLA-DRCD4T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: Reversal with IL-10
    • Ludviksson BR, SnellerMC, Chua KS, et al. Active Wegener's granulomatosis is associated with HLA-DRCD4T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: Reversal with IL-10. J Immunol 1998; 160:3602- 3609.
    • (1998) J Immunol , vol.160 , pp. 3602-3609
    • Ludviksson, B.R.1    Sneller, M.C.2    Chua, K.S.3
  • 33
    • 0036796830 scopus 로고    scopus 로고
    • Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitis: An open pilot study on 10 patients
    • Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitis: An open pilot study on 10 patients. Rheumatology (Oxford) 2002; 41:1126-1132.
    • (2002) Rheumatology (Oxford) , vol.41 , pp. 1126-1132
    • Bartolucci, P.1    Ramanoelina, J.2    Cohen, P.3
  • 34
    • 0035033807 scopus 로고    scopus 로고
    • Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety
    • Stone JH, Uhlfelder ML, Hellmann DB, et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety. Arthritis Rheum 2001; 44:1149-1154.
    • (2001) Arthritis Rheum , vol.44 , pp. 1149-1154
    • Stone, J.H.1    Uhlfelder, M.L.2    Hellmann, D.B.3
  • 35
    • 12544253745 scopus 로고    scopus 로고
    • Etanercept plus standard therapy for Wegener's granulomatosis
    • Wegener's Granulomatosis Etanercept Trial (WGET) Research Group
    • Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351-361.
    • (2005) N Engl J Med , vol.352 , pp. 351-361
  • 36
    • 77957240329 scopus 로고    scopus 로고
    • Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement
    • Laurino S, Chaudhry A, Booth A, et al. Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol Dial Transplant 2010; 25:3307-3314.
    • (2010) Nephrol Dial Transplant , Issue.25 , pp. 3307-3314
    • Laurino, S.1    Chaudhry, A.2    Booth, A.3
  • 37
    • 1542288825 scopus 로고    scopus 로고
    • Prospective study of TNFalphablockade with infliximab in antineutrophil cytoplasmic antibody-associated systemic vasculitis
    • Booth A, Harper L, Hammad T, et al. Prospective study of TNFalphablockade with infliximab in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am SocNephrol 2004; 15:717-721.
    • (2004) J Am SocNephrol , vol.15 , pp. 717-721
    • Booth, A.1    Harper, L.2    Hammad, T.3
  • 38
    • 0000752307 scopus 로고    scopus 로고
    • In vitro up-regulation of E-selectin and induction of interleukin-6 in endothelial cells by autoantibodies in Wegener's granulomatosis and microscopic polyangiitis
    • Kobold ACM, Wijk RTV, Franssen CFM, et al. In vitro up-regulation of E-selectin and induction of interleukin-6 in endothelial cells by autoantibodies in Wegener's granulomatosis and microscopic polyangiitis. Clin Exp Rheumatol 1999; 17:433-440.
    • (1999) Clin Exp Rheumatol , vol.17 , pp. 433-440
    • Kobold, A.C.M.1    Wijk, R.T.V.2    Franssen, C.F.M.3
  • 39
    • 80053159298 scopus 로고    scopus 로고
    • Complete remission of myeloperoxidaseantineutrophilcytoplasmicantibody- Associatedcrescentglomerulonephritiscomplicatedwithrheumatoidarthritisusing a humanized antiinterleukin 6 receptor antibody
    • Sumida K, Ubara Y, Suwabe T, et al. Complete remission of myeloperoxidaseantineutrophilcytoplasmicantibody- Associatedcrescentglomerulonephritiscomplicatedwithrheumatoidarthritisusing a humanized antiinterleukin 6 receptor antibody. Rheumatology (Oxford) 2011; 50:1928-1930.
    • (2011) Rheumatology (Oxford) , vol.50 , pp. 1928-1930
    • Sumida, K.1    Ubara, Y.2    Suwabe, T.3
  • 40
    • 79551667105 scopus 로고    scopus 로고
    • Myeloperoxidase-specific plasma cell depletion by bortezomib protects from antineutrophil cytoplasmic autoantibodies- induced glomerulonephritis
    • Bontscho J, Schreiber A, Manz RA, et al. Myeloperoxidase-specific plasma cell depletion by bortezomib protects from antineutrophil cytoplasmic autoantibodies- induced glomerulonephritis. J Am SocNephrol 2011; 22:336- 348.
    • (2011) J Am SocNephrol , Issue.22 , pp. 336-348
    • Bontscho, J.1    Schreiber, A.2    Manz, R.A.3
  • 41
    • 1542348997 scopus 로고    scopus 로고
    • Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcgamma receptors and CD18
    • Hewins P, Williams JM, Wakelam MJ, Savage CO. Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcgamma receptors and CD18. J Am SocNephrol 2004; 15:796-808.
    • (2004) J Am SocNephrol , vol.15 , pp. 796-808
    • Hewins, P.1    Williams, J.M.2    Wakelam, M.J.3    Savage, C.O.4
  • 42
    • 39749146417 scopus 로고    scopus 로고
    • Treatment of Churg-Strauss syndrome without poor-prognosis factors: Amulticenter, prospective, randomized, openlabel study of seventy-two patients
    • Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: Amulticenter, prospective, randomized, openlabel study of seventy-two patients. Arthritis Rheum 2008; 58:586-594.
    • (2008) Arthritis Rheum , vol.58 , pp. 586-594
    • Ribi, C.1    Cohen, P.2    Pagnoux, C.3
  • 43
    • 45749109391 scopus 로고    scopus 로고
    • Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production
    • Pepper RJ, Fabre MA, Pavesio C, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008; 47:1104- 1105.
    • (2008) Rheumatology (Oxford) , vol.47 , pp. 1104-1105
    • Pepper, R.J.1    Fabre, M.A.2    Pavesio, C.3
  • 44
    • 80053215159 scopus 로고    scopus 로고
    • Rituximab for the treatment of Churg-Strauss syndrome with renal involvement
    • Cartin-Ceba R, Keogh KA, Specks U, et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 2011; 26:2865-2871.
    • (2011) Nephrol Dial Transplant , Issue.26 , pp. 2865-2871
    • Cartin-Ceba, R.1    Keogh, K.A.2    Specks, U.3
  • 45
    • 77952737931 scopus 로고    scopus 로고
    • Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome
    • Kim S, Marigowda G, Oren E, et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125:1336-1343.
    • (2010) J Allergy Clin Immunol , Issue.125 , pp. 1336-1343
    • Kim, S.1    Marigowda, G.2    Oren, E.3
  • 46
    • 80052509804 scopus 로고    scopus 로고
    • Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome
    • Moosig F, Gross WL, Herrmann K, et al. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 2011; 155:341- 343.
    • (2011) Ann Intern Med , Issue.155 , pp. 341-343
    • Moosig, F.1    Gross, W.L.2    Herrmann, K.3
  • 47
    • 77954591017 scopus 로고    scopus 로고
    • Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: A long-term observational study
    • Metzler C, Csernok E, Gross WL, Hellmich B. Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: A long-term observational study. Clin Exp Rheumatol 2010; 28:24-30.
    • (2010) Clin Exp Rheumatol , Issue.28 , pp. 24-30
    • Metzler, C.1    Csernok, E.2    Gross, W.L.3    Hellmich, B.4
  • 48
    • 84864014453 scopus 로고    scopus 로고
    • Genetically Distinct Subsets within ANCA-associated Vasculitis
    • Lyons PA, Rayner TF, Trivedi S, et al. Genetically Distinct Subsets within ANCA-associated Vasculitis. N Engl J Med 2012; 367:214-223.
    • (2012) N Engl J Med , Issue.367 , pp. 214-223
    • Lyons, P.A.1    Rayner, T.F.2    Trivedi, S.3
  • 49
    • 84883258487 scopus 로고    scopus 로고
    • Clinical outcomes of remission induction therapy for severe ANCA-associated vasculitis
    • Miloslavsky E, Specks U, Merkel P, et al. Clinical outcomes of remission induction therapy for severe ANCA-associated vasculitis. Arthritis Rheum 2013; 65:2441-2449.
    • (2013) Arthritis Rheum , Issue.65 , pp. 2441-2449
    • Miloslavsky, E.1    Specks, U.2    Merkel, P.3
  • 50
    • 68549128699 scopus 로고    scopus 로고
    • Extracorporeal membrane oxygenation for the management of respiratory failure caused by diffuse alveolar hemorrhage
    • Guo Z, Li X, Jiang LY, Xu LF. Extracorporeal membrane oxygenation for the management of respiratory failure caused by diffuse alveolar hemorrhage. J Extra Corpor Technol 2009; 41:37-40
    • (2009) J Extra Corpor Technol , vol.41 , pp. 37-40
    • Guo, Z.1    Li, X.2    Jiang, L.Y.3    Xu, L.F.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.